Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2016-04-20
|
CA-170 |
|
preclinical |
Curis (USA - MA) Aurigene (India) |
Cancer - Oncology |
2016-04-20
|
CA-4948 |
|
preclinical |
Curis (USA - MA) Aurigene (India) |
Cancer - Oncology |
2016-04-20
|
AUPM-327 |
|
preclinical |
Curis (USA - MA) Aurigene (India) |
Cancer - Oncology |
2016-04-19
|
sacituzumab govitecan - IMMU-132 |
relapsed or refractory metastatic urothelial cancer |
2 |
Immunomedics (USA - NJ) |
Cancer - Oncology |
2016-04-19
|
emixustat hydrochloride |
geographic atrophy (GA) associated with dry age-related macular degeneration (AMD) |
2b-3 |
Acucela (USA - MA) Otsuka Pharmaceuticals (Japan) |
Ophtalmological diseases |
2016-04-19
|
ABP 798 (biosimilar version of Mabthera®/Rituxan® - rituximab) |
non-Hodgkin lymphoma |
3 |
Amgen (USA - CA) |
Cancer - Oncology |
2016-04-19
|
lenvatinib in combination with everolimus |
kidney cancer |
preclinical |
Eisai (Japan) |
Cancer - Oncology |
2016-04-19
|
GITRL-Fc |
|
preclinical |
OncoMed Pharmaceuticals (USA - CA) |
Cancer - Oncology |
2016-04-19
|
new generation oncolytic viral immunotherapy product candidate |
|
preclinical |
Transgene (France) |
Cancer - Oncology |
2016-04-19
|
IPH52 |
|
preclinical |
Innate Pharma (France) Orega Biotech (France) |
Cancer - Oncology |
2016-04-19
|
AP32788 |
|
preclinical |
Ariad Pharmaceuticals (USA - MA) |
Cancer - Oncology |
2016-04-19
|
IMO-2125 in combination with an inhibitor of the immunosuppressive enzyme, indoleamine-pyrrole 2,3-dioxygenase (IDO1) |
|
|
Idera Pharmaceuticals (USA - CA) |
Cancer - Oncology |
2016-04-18
|
IMMU-114 |
chronic lymphocytic leukemia, acute lymphoblastic leukemia |
preclinical |
Immunomedics (USA - NJ) |
Cancer - Oncology |
2016-04-18
|
PEG-ADA2 |
|
preclinical |
Halozyme Therapeutics (USA - CA) |
Cancer - Oncology |
2016-04-18
|
HTI-1511 |
|
preclinical |
Halozyme Therapeutics (USA - CA) |
Cancer - Oncology |
2016-04-18
|
varlilumab and Opdivo® (nivolumab) |
advanced non-small cell lung cancer (NSCLC), metastatic melanoma (MEL), colorectal cancer (CRC), ovarian cancer, and head and neck squamous cell carcinoma (SCCHN) |
1-2a |
Celldex Therapeutics (USA - NJ) BMS (USA - NY) |
Cancer - Oncology |
2016-04-18
|
ARC-HIF2 |
clear cell renal cell carcinoma |
preclinical |
Arrowhead Research Corporation (USA - CA) |
Cancer - Oncology |
2016-04-18
|
AZD2014 (vistusertib) |
diffuse large B-cell mymphoma |
2 |
AstraZeneca (UK) University of Birmingham (UK) |
Cancer - Oncology |
2016-04-18
|
TGR-1202 |
|
preclinical |
TG Therapeutics (USA - NY) |
|
2016-04-18
|
Livatag® (doxorubicin Transdrug®) |
hepatocellular carcinoma |
|
Onxeo (France) |
Cancer - Oncology |